EyePoint Pharmaceuticals Q2 2020 Earnings Report
Key Takeaways
EyePoint Pharmaceuticals reported Q2 2020 financial results, with total revenues of $4.1 million and net product revenues of $3.7 million, impacted by the COVID-19 pandemic. A U.S. commercial alliance with ImprimisRx was established to expand the reach of DEXYCU. Jay S. Duker, M.D., joined as Chief Strategic Scientific Officer to lead EYP-1901 development efforts. EYP-1901 remains on track for a Q4 IND filing.
Total revenues reached $4.1 million, with net product revenues at $3.7 million, influenced by the COVID-19 pandemic.
A U.S. commercial alliance with ImprimisRx was formed to broaden the reach of DEXYCU.
Jay S. Duker, M.D., was appointed as Chief Strategic Scientific Officer to spearhead EYP-1901 development.
EYP-1901 is on track for a Q4 IND filing.
EyePoint Pharmaceuticals
EyePoint Pharmaceuticals
EyePoint Pharmaceuticals Revenue by Segment
Forward Guidance
EyePoint expects that its cash and cash equivalents combined with projected cash inflows from anticipated YUTIQ and DEXYCU product sales and other expected financing activities can fund the Company’s operating plan into 2021 under current assumptions for the duration of the COVID-19-related closures across the U.S.